Stifel raised the firm’s price target on Spyre Therapeutics (SYRE) to $54 from $36 and keeps a Buy rating on the shares. The recent data from Apogee Therapeutics (APGE) and Astria Therapeutics (ATXS) provide further support for the translatability of preclinical YTE antibody data into humans, and the firm is increasing its probability of success for Spyre’s lead program, SPY001, while also boosting its peak penetration estimates on the heels of more recent NHP half-life data presented at ECCO, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics Secures $180M in Strategic Financial Move
- Spyre Therapeutics announces $180M private placement
- Spyre Therapeutics price target raised to $50 from $44 at Guggenheim
- GoodRx upgraded, Fisker downgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades Spyre Therapeutics on SY001 half-life extension
